Kite Pharma, a unit of Gilead Sciences Inc, has entered into a strategic collaboration with Gadeta BV, a privately-held Dutch company, to discover and develop gamma delta T cell receptor (TRC) therapies for cancer. Kite’s first product, a chimeric antigen receptor T cell therapy, has been approved by the US Food and Drug Administration for lymphoma. The company’s collaboration with Gadeta is focused on the treatment of solid tumours.
